Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 58

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 58
---
12.6 million. The combined effective offering price for each share and accompanying Private Placement Warrant in the Private Placement was $2.65. Pursuant to the Securities Purchase Agreement, each Purchaser was obligated to purchase such Purchaser’s respective investment in the Private Placement in four equal tranches, as follows:

| • |     | $2.23 million was purchased on June 2, 2025 (the “Initial Closing”); |

| • |     | $2.23 million was purchased on June 9, 2025, following our notification to the Purchasers that the Food                                                                                                                                          
 and Drug Administration (FDA) has notified us that we are no longer subject to the partial clinical hold set forth in the FDA’s Partial Clinical Hold letter to us dated January 24, 2024, with respect to our planned Phase 3 trial of IFx-2.0; |

| • |     | $2.23 million was purchased on June 24, 2025, following our notification to the Purchasers that the 
 Phase 3 trial for IFx-Hu2.0 (the “Phase 3 Trial”) had been initiated; and                           |

| • |     | $2.23 million was purchased on June 30, 2025, following our notification to the Purchasers that all                                                                                                                                                 
 material conditions for the closing of the Kineta Merger have been satisfied (other than conditions that cannot be satisfied until on or immediately before the closing of the Kineta Merger) and that we were prepared to close the Kineta Merger. |

In addition to the approximately $8.9 million that was purchased in four tranches through July 24, 2025, under the Securities Purchase Agreement, approximately $3.7 million of the Private Placement (the “Final Tranche Private Placement Amount”) was required under the Securities Purchase Agreement to be purchased and funded by December 31, 2025 by four Purchasers who had the right defer the purchase of a portion of their Common Stock and Private Placement Warrants until such time (the “Deferral Investors”). The Deferral Investors were Pranabio Investments LLC, Garden Street House, LLC, Thomas C. Mollick, and Matthew Nachtrab. On September 5, 2025, each of Deferral Investors and us entered into an agreement (the “Final Purchase Agreements”) pursuant to which they agreed to immediately purchase an aggregate of $3.2 million of the Final Tranche Private Placement Amount in exchange